Skip to content

How Different Sedatives Affect Hip Fracture Patient's Postoperative Delirium

Influence on Incidence of Postoperative Delirium by Various Sedatives in Elderly Patients With Hip Fracture Under Lumbar Anesthesia: A Randomized, Control and Multi-center Trial

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03346226
Enrollment
1000
Registered
2017-11-17
Start date
2018-01-01
Completion date
2019-06-30
Last updated
2017-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium in Old Age

Keywords

Delirium Dexmedetomidine elderly

Brief summary

the hypothesis is that Dexmedetomidine seems to decrease incidence of post-operative delirium . one possible mechanism is that Dex have a minor influence on cognition, since it has no effect on GABA receptor,another is that Dex could induce a sleep similar to natural sleep, thereby decreasing sleep deprivation and circadian rhythm disorder in post-operative patients. In this study , investigators devise the two different sedatives(Dexmedetomidine and Propofol)'influence on postoperative delirium in hip fracture elderly participants under spinal anesthesia

Detailed description

With a complex etiology, delirium is usually caused by various peri-operative stimuli on basis of predisposing factors, including senility, hypoxia and hypotension, pain, drug (such as pethidine, benzodiazepine, anticholinergic, and drug withdrawal), complications prior to surgery, post-operative sleep disorder. As for the mechanism of delirium, the commonly accepted hypothesis includes the decreased central cholinergic neurons function and the inflammation of central nervous system. Most of the hip fracture patients are senile, suffering generally from many complications with exposure to many drugs, and poor in nutritional status with decreased cognitive function even before the surgery in some of them, all of which are risk factors for post-operative delirium. Systematic review suggests that incidence of POD in patients undergoing elective hip arthroplasty is up to 4-53.3%. It is of great importance, therefore, to explore the effective approaches to lower POD incidence in senile patients with operation on hip fracture. Dexmedetomidine Hydrochloride is a novel highly-selective α2 adrenergic receptor agonist, and its selectivity to α2 receptor is 8 times of that of clonidine. It has multiple functions including sedation, anti-anxiety, hypnosis, analgesia and sympathetic blockade, with a wide application prospect for peri-operative patients. Researches suggest that Dex applied peri-operatively may stabilize blood pressure and heart rate, control intra-operative stress, and decrease post-operative side reactions such as nausea, vomiting, restlessness, delirium and chills. Moreover, advantages of Dex also include analgesia and reduction of opioid usage. Clinical pharmacological characteristics of Dex suggest its possible function to decrease post-operative delirium. Meanwhile, Dex seems to have a minor influence on cognition, since it has no effect on GABA receptor. Another important feature of it is that Dex induces a sleep similar to natural sleep, thereby decreasing sleep deprivation and circadian rhythm disorder in post-operative patients, and decreasing incidence of post-operative delirium. Researches evaluating the capability of Dex to decrease delirium incidence are focused on ICU sedation post to operation. Riker et al compared the sedative effect between Dex and midazolam in patients with severe mechanical ventilation, revealing a lower delirium incidence in Dex than in midazolam (54.0% vs 76.6%) in patients maintained with the same depth of sedation. Systematic review concludes that Dex in effective to prevent and treat post-operative delirium in ICU patients. In this study ,the investigators devise the two different sedatives (Dexmedetomidine and Propofol)'influence on postoperative delirium in hip fracture elderly participants under spinal anesthesia

Interventions

DRUGDexmedetomidine Hydrochloride

Dexmedetomidine is given to patients during spinal anesthesia at the dose of 0.5 μg/kg,adjusted the dose to keep BIS between 70-80 until 30 minutes before the end of surgery

DRUGPropofol

Propofol is given with an initial ratio of 2-10mg/kg/h, when the operation starts,adjust the propofol's dose to keep BIS between 70-80 before the end of surgery

Sponsors

First Affiliated Hospital of Guangxi Medical University
CollaboratorOTHER
The Second Affiliated Hospital of Harbin Medical University
CollaboratorOTHER
The First Affiliated Hospital of Nanchang University
CollaboratorOTHER
Qianfoshan Hospital
CollaboratorOTHER
Shanghai 6th People's Hospital
CollaboratorOTHER
Tang-Du Hospital
CollaboratorOTHER
Second Hospital of Shanxi Medical University
CollaboratorOTHER
The First Affiliated Hospital of Soochow University
CollaboratorOTHER
Shanghai Changzheng Hospital
CollaboratorOTHER
The Fuzhou No 2 Hospital
CollaboratorOTHER
Foshan Hospital of Traditional Chinese Medicine
CollaboratorOTHER
Beijing Jishuitan Hospital
CollaboratorOTHER
Shanghai Zhongshan Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Masking description

the intervention is happend in the operation,the outcome assessment is going after the operation

Intervention model description

Dexmedetomidine group:dexmedetomidine is given to patients under spinal anesthesia until the end of surgery propofol group:Propofol is given to patients uunder spinal anesthesia until the end of surgery

Eligibility

Sex/Gender
ALL
Age
65 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

1. Acquisition of informed consent, 2. Patients with hip fracture surgery under lumbar anesthesia, 3. Grade II to III based on American Society of Anesthesiologists ASA classification, 4. Age ≥65 and ≤90 years old.

Exclusion criteria

1. History of psychiatric disease or a disease needing long-term exposure to psychotropic drugs (dementia, schizophrenia), or history of alcoholic abuse. 2. More than 8 errors in preoperative Simplified Psychology and Mental Status Questionnaire (SPMSQ) , and diagnosed as severe cognitive impairment. 3. CAM positive diagnosed preoperatively. 4. Any cerebrovascular accident occurring within 3 months, such as cerebral stroke or transient ischemic attack (TIA). 5. Systolic pressure \< 90mmHg and diastolic pressure \< 60mm Hg at the preoperative follow up or HR\< 50/minute. 6. History of heat failure or EF\<30% as shown by ultrasound cardiogram; degree 2 type 2 and degree 3 atrioventricular block. History of active heart disease (such as acute cardiac infarction, unstable angina pectoris) 7. Severe abnormality in hepatic or renal function (severe abnormality in liver function: more than 2-times increase than upper normal limit in any one of the markers including ALT,, conjugated bilirubin, AST, ALP, total bilirubin; severe abnormality in renal function; Cr clearance\<30ml/min), Scr\>443μmol/L. 8. Diabetes patients with severe complications of diabetes (Diabetic ketoacidosis, hyperosmolar coma, various infections, macrovascular diseases, and diabetic nephropathy) 9. Patients with severe infection. 10. Postoperative PaO2\<60mmHg or SpO2\<92%. 11. Participation in clinical trials of other drugs within past 30 days. 12. Disturbed verbal communication, and unable to accomplish the test on cognition. 13. Patients with prosthesis fracture or restoration; hip fracture but complicated with severe trauma in other sites. 14. Being allergic to investigational drug or having contradiction of lumbar anesthesia.

Design outcomes

Primary

MeasureTime frameDescription
occurrence of postoperative delirium in postoperative 72 hourspatient enrolled will be evaluated at 9Am and 3Pm during post-operative day 1-3 (POD1-3).At any time point above,delirium is detected,then the patient will be diagnosed as postoperative delirium. All patients enrolled is Non-delirium before surgery。Evaluation of delirium is performed by trained investigational assistant who does not know the randomization of patients. Follow up is carried out before operation and at 9Am and 3Pm during post-operative day 1-3 (POD1-3). During follow up, RASS (Richmond Agitation-Sedation Scale, RASS) is used firstly to evaluate sedation of the patients, and for those with ARSS \>-4 (-3~+4), the Confusion Assessment Method (CAM) is adopted for evaluation. A case consistent with delirium standard at any time point during follow up is determined to be delirium positive. Diagnosis should be confirmed for a CAM-positive patient by a psychological expert based on DSM-V standard

Secondary

MeasureTime frameDescription
Times of intra-operative occurrence of hypotension, bradycardia, hypertension and tachycardia that need treatment.during the operationassess the adverse effect of anaesthetic
Score of quality of post-operative sleepingquality of sleeping will be assessed at 9Am during post-operative day 1-3Score of sleeping quality is evaluated based on the some questions during follow up
Hospital stayrecord the days of hospital stay at the 30 days after surgerythe duration from the day of operation to the date meeting discharge criteria as determined by doctor in charge
Consumption of analgesicrecord the data of comsumption of analgeisic at 48 hours after operationthe patients will receive patient-controlled intravenous analgesia,record the consumption of intravenous analgesia in the 48 postoperative hours
Mortality up to day 30 post to operationthe data will be collected after 30 days of operationData for 30-day survival is collected through telephone follow up by the assistant.
pain scorePain score will be evaluated at time point of operation, 1,6,24, 48 hours after operation, using NRS scoredescribe severity of the pain the patient feel using Numerical Rating Scale (NRS)
Post-operative complications besides deliriumobserve and evaluate complications at the 30 days after surgerycomplications besides delirium ,such as vomiting,nausea,hypotention,hypertention,bradycardia

Contacts

Primary ContactZhang XiaoGuang, Doctor
zhangxg@fudan.edu.cn+86 13641995733

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026